| pubmed-article:8730501 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8730501 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:8730501 | lifeskim:mentions | umls-concept:C0002199 | lld:lifeskim |
| pubmed-article:8730501 | lifeskim:mentions | umls-concept:C0524910 | lld:lifeskim |
| pubmed-article:8730501 | pubmed:dateCreated | 1996-10-2 | lld:pubmed |
| pubmed-article:8730501 | pubmed:abstractText | Alpha interferon (alpha IFN) treatment normalizes serum ALT levels in at least half of all patients affected by chronic hepatitis C, but a reactivation of the disease is frequently observed after the end of therapy. Different regimens of alpha IFN therapy have been proposed but the optimal schedule is still controversial. Recently at least 6 different types of HCV have been identified and the HCV genotype has been proposed as an important factor influencing the response to alpha IFN therapy. | lld:pubmed |
| pubmed-article:8730501 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8730501 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8730501 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8730501 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8730501 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8730501 | pubmed:issn | 0392-856X | lld:pubmed |
| pubmed-article:8730501 | pubmed:author | pubmed-author:BellobuonoAA | lld:pubmed |
| pubmed-article:8730501 | pubmed:author | pubmed-author:BellatiGG | lld:pubmed |
| pubmed-article:8730501 | pubmed:author | pubmed-author:TempiniSS | lld:pubmed |
| pubmed-article:8730501 | pubmed:author | pubmed-author:SiliniEE | lld:pubmed |
| pubmed-article:8730501 | pubmed:author | pubmed-author:IdéoGG | lld:pubmed |
| pubmed-article:8730501 | pubmed:author | pubmed-author:MondazziLL | lld:pubmed |
| pubmed-article:8730501 | pubmed:author | pubmed-author:IdéoG MGM | lld:pubmed |
| pubmed-article:8730501 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8730501 | pubmed:volume | 13 Suppl 13 | lld:pubmed |
| pubmed-article:8730501 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8730501 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8730501 | pubmed:pagination | S167-73 | lld:pubmed |
| pubmed-article:8730501 | pubmed:dateRevised | 2010-3-24 | lld:pubmed |
| pubmed-article:8730501 | pubmed:meshHeading | pubmed-meshheading:8730501-... | lld:pubmed |
| pubmed-article:8730501 | pubmed:meshHeading | pubmed-meshheading:8730501-... | lld:pubmed |
| pubmed-article:8730501 | pubmed:meshHeading | pubmed-meshheading:8730501-... | lld:pubmed |
| pubmed-article:8730501 | pubmed:meshHeading | pubmed-meshheading:8730501-... | lld:pubmed |
| pubmed-article:8730501 | pubmed:meshHeading | pubmed-meshheading:8730501-... | lld:pubmed |
| pubmed-article:8730501 | pubmed:meshHeading | pubmed-meshheading:8730501-... | lld:pubmed |
| pubmed-article:8730501 | pubmed:meshHeading | pubmed-meshheading:8730501-... | lld:pubmed |
| pubmed-article:8730501 | pubmed:meshHeading | pubmed-meshheading:8730501-... | lld:pubmed |
| pubmed-article:8730501 | pubmed:meshHeading | pubmed-meshheading:8730501-... | lld:pubmed |
| pubmed-article:8730501 | pubmed:meshHeading | pubmed-meshheading:8730501-... | lld:pubmed |
| pubmed-article:8730501 | pubmed:meshHeading | pubmed-meshheading:8730501-... | lld:pubmed |
| pubmed-article:8730501 | pubmed:articleTitle | Alpha interferon treatment in chronic hepatitis C. | lld:pubmed |
| pubmed-article:8730501 | pubmed:affiliation | Center for Liver Diseases Crespi, Niguarda Hospital, Milan, Italy. | lld:pubmed |
| pubmed-article:8730501 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8730501 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:8730501 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8730501 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8730501 | lld:pubmed |
